Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma
Status:
Active, not recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
This research study is studying a combination of drugs as a possible treatment for
unresectable or metastatic melanoma.
The drugs involved in this study are:
- Pembrolizumab (Keytruda)
- Trametinib (Mekinist)
- Dabrafenib (Tafinlar)